國立虎尾科技大學 |

Crystal Structure of the Human Cytochrome P450 2C9*8 Genetic Variant.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Crystal Structure of the Human Cytochrome P450 2C9*8 Genetic Variant./
作者:	Kamat, Sumit S.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	48 p.
附註:	Source: Masters Abstracts International, Volume: 82-03.
Contained By:	Masters Abstracts International82-03.
標題:	Biochemistry. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28086898
ISBN:	9798662591103

Crystal Structure of the Human Cytochrome P450 2C9*8 Genetic Variant.
Kamat, Sumit S.

Crystal Structure of the Human Cytochrome P450 2C9*8 Genetic Variant. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 48 p.

Source: Masters Abstracts International, Volume: 82-03.

Thesis (M.S.)--Albany College of Pharmacy and Health Sciences, 2020.

This item must not be sold to any third party vendors.

Cytochrome P450 (CYP) enzymes are one of the major xenobiotic metabolizing enzymes with increasing importance in pharmacogenetics. The human CYP2C9 enzyme that metabolizes over 15% of clinical drugs including warfarin, losartan, tolbutamide, etc. is highly polymorphic with more than eighty genetic variations identified thus far. Many of these variants have demonstrated significantly reduced activity compared with the wild-type (WT) enzyme. The CYP2C9*8 allele, prevalent among different populations and predominantly found in African-Americans with a frequency of around 0.06, is associated with altered clearance of several drug substrates of CYP2C9. The *8 represents an amino acid variation from arginine to histidine at position 150 (R150H). The R150H variant was generated using CYP2C9 WT construct by site-directed mutagenesis, and the enzyme was expressed in E. coli followed by protein purification and crystallization. The CYP2C9*8 was crystallized in the presence of the drug substrate losartan and the structure was determined using X-ray crystallography at 2.3 A resolution. The R150H, found on the surface of the protein on D-helix that is distal from the active site, illustrates minimal effect on the overall conformation of the protein compared to the WT. Despite subtle changes in the structure itself, there were clear differences in the binding of losartan compared to the previously solved CYP2C9 WT complex. One molecule of losartan was bound in the active site and one on the surface, consistent to that observed in the WT complex. However, unlike the WT complex, the losartan in the access channel was not observed in the *8 complex. In addition, the losartan turn-over rates measured using enzymatic assays differed significantly, with the variant demonstrating marked reduction in activity than the WT enzyme. The results yield insight into the role of simultaneous binding of multiple substrate molecules that may suggest a possible role of cooperativity and altered hydroxylation profile of losartan with this variant. Further studies are warranted to determine the role of such distal variation.

ISBN: 9798662591103Subjects--Topical Terms:

582831
Biochemistry.
Subjects--Index Terms:

CYP2C9*8

Crystal Structure of the Human Cytochrome P450 2C9*8 Genetic Variant.
LDR:03311nam a2200385 4500 001 1038018
005 20210910100656.5
008 211029s2020 ||||||||||||||||| ||eng d
020 $a 9798662591103
035 $a (MiAaPQ)AAI28086898
035 $a AAI28086898
040 $a MiAaPQ $c MiAaPQ
100 1 $a Kamat, Sumit S. $3 1335345
245 1 0 $a Crystal Structure of the Human Cytochrome P450 2C9*8 Genetic Variant.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 48 p.
500 $a Source: Masters Abstracts International, Volume: 82-03.
500 $a Advisor: Shah, Manish B.
502 $a Thesis (M.S.)--Albany College of Pharmacy and Health Sciences, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Cytochrome P450 (CYP) enzymes are one of the major xenobiotic metabolizing enzymes with increasing importance in pharmacogenetics. The human CYP2C9 enzyme that metabolizes over 15% of clinical drugs including warfarin, losartan, tolbutamide, etc. is highly polymorphic with more than eighty genetic variations identified thus far. Many of these variants have demonstrated significantly reduced activity compared with the wild-type (WT) enzyme. The CYP2C9*8 allele, prevalent among different populations and predominantly found in African-Americans with a frequency of around 0.06, is associated with altered clearance of several drug substrates of CYP2C9. The *8 represents an amino acid variation from arginine to histidine at position 150 (R150H). The R150H variant was generated using CYP2C9 WT construct by site-directed mutagenesis, and the enzyme was expressed in E. coli followed by protein purification and crystallization. The CYP2C9*8 was crystallized in the presence of the drug substrate losartan and the structure was determined using X-ray crystallography at 2.3 A resolution. The R150H, found on the surface of the protein on D-helix that is distal from the active site, illustrates minimal effect on the overall conformation of the protein compared to the WT. Despite subtle changes in the structure itself, there were clear differences in the binding of losartan compared to the previously solved CYP2C9 WT complex. One molecule of losartan was bound in the active site and one on the surface, consistent to that observed in the WT complex. However, unlike the WT complex, the losartan in the access channel was not observed in the *8 complex. In addition, the losartan turn-over rates measured using enzymatic assays differed significantly, with the variant demonstrating marked reduction in activity than the WT enzyme. The results yield insight into the role of simultaneous binding of multiple substrate molecules that may suggest a possible role of cooperativity and altered hydroxylation profile of losartan with this variant. Further studies are warranted to determine the role of such distal variation.
590 $a School code: 1732.
650 4 $a Biochemistry. $3 582831
650 4 $a Molecular biology. $3 583443
650 4 $a Pharmacology. $3 583819
650 4 $a Pharmaceutical sciences. $3 1180569
653 $a CYP2C9*8
653 $a Cytochrome P450
653 $a Enzyme Assays
653 $a Protein Expression and Purification
653 $a X-Ray Crystallography
690 $a 0572
690 $a 0487
690 $a 0419
690 $a 0307
710 2 $a Albany College of Pharmacy and Health Sciences. $b Pharmaceutical Sciences. $3 1335346
773 0 $t Masters Abstracts International $g 82-03.
790 $a 1732
791 $a M.S.
792 $a 2020
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28086898